Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)
NCT01244230
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
fexofenadine/Allegra (M016455)
Sponsor
Sanofi